<DOC>
	<DOCNO>NCT01430442</DOCNO>
	<brief_summary>The purpose study exploration wide range BMS-927711 dose reveal least one dose safe clinically superior placebo treatment acute migraine .</brief_summary>
	<brief_title>Dose Ranging Study Drug Treatment Acute Migraine</brief_title>
	<detailed_description>Intervention Model : Parallel Versus Comparator + Placebo</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Patient least 1 year history migraine ( without aura ) include follow ; Migraine attack 1 year age onset prior 50 year age ; Migraine attack , average , last 4 72 hour untreated ; No 8 attack moderate severe intensity per month within last 3 month ; Patient must able distinguish migraine attack tension/cluster attack must consistent migraine headache least 2 migraine headache attack severe moderate intensity last 3 month ; Less 15 day headache ( migraine non migraine ) per month 3 month prior screen ; Male female ≥ 18 year ≤ age 65 No clinically significant abnormality identify medical laboratory evaluation Patient history basilar migraine hemiplegic migraine Patient receive migraine relief triptan migraine treatment Medications may alter pH stomach ( acid reduce agent ) , H2 antagonists , Proton Pump inhibitor ( PPI ) , antacids History ergotamine triptan intake great than/equal 10 day per month regular basis great 3 month History nonnarcotic analgesic intake great then/equal 15 day per month great than/equal 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>